RxDoctor Payments Data

Neil Singer, MD

Internal Medicine · Sedona, AZNPI 1043277478

Payments from drug & device makers

$1,404in general payments, 2019–2025

Across 70 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$452
  • AstraZeneca$445
  • Amarin Pharma, Inc.$141
  • Johnson & Johnson$124
  • AbbVie$86
  • Biohaven Pharmaceutical Holding Company Ltd.$42
  • plus $114 from 7 others

What the payments were for

  • Food & beverage$1,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,404 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$208,336
Medicare patients
391
Services billed
10,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$151,436
OzempicSemaglutide83$103,744
XareltoRivaroxaban33$50,900
JardianceEmpagliflozin38$45,836
FarxigaDapagliflozin Propanediol32$41,928
JanuviaSitagliptin Phosphate26$41,142
MounjaroTirzepatide34$36,372
MyrbetriqMirabegron36$31,869
OxycontinOxycodone Hcl14$27,938
IsentressRaltegravir Potassium11$24,635
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$20,718
Janumet XrSitagliptin Phos/Metformin Hcl15$19,528
LinzessLinaclotide18$14,809
BelbucaBuprenorphine Hcl18$14,037
PremarinEstrogens, Conjugated14$8,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$18$159,563159 claims
Johnson & JohnsonXarelto$124$50,90033 claims
AstraZenecaFarxiga$445$41,92832 claims
Lilly USA, LLCMounjaro$20$36,37234 claims
AbbVieLinzess, Synthroid$86$20,38189 claims
Kowa Pharmaceuticals America, Inc.Livalo$11$3,39911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Sedona

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →